Such imaging could be used, for example, to monitor plaques as they build up in blood vessels.
Herein, we report synthesis, characterization and crystal structure of (Z -5- 2- 5- 2-fluoroethoxy benzo[d Z -5- 2- 5- 2-fluoroethoxy benzo[d Z -5- 2- 5- 2-fluoroethoxy benzo[d Z -5- 2- 5- 2-fluoroethoxy benzo[d Z -5- 2- 5- 2-fluoroethoxy benzo[d Z -5- 2- 5- 2-fluoroethoxy benzo[dal to serve as an Aβ-targeted PET radiopharmaceutical for monitoring plaque burden in AD.
Herein, we report synthesis and characterization of (E -5- 2- 6- 2-[18F]-fluoroethoxy -benzo[d]thiazol-2-yl)vinyl)-N,N-dimE -5- 2- 6- 2-[18F]-fluoroethoxy -benzo[d]thiazol-2-yl-7B), and pE -5- 2- 6- 2-[18F]-fluoroethoxy -benzo[d]thiazol-2-ylntial to sE -5- 2- 6- 2-[18F]-fluoroethoxy -benzo[d]thiazol-2-ylitoring plaquE -5- 2- 6- 2-[18F]-fluoroethoxy -benzo[d]thiazol-2-yl
However, a significant increase in plaque volume was only detected if we monitored plaque sizes for more than 16 days (Supplementary Fig. S2).
Since virus isolates consist of quasi-species, monitoring plaque purified viruses or viruses generated from plasmid clones has to be considered for phenotypic assays.
We monitored plaques for six consecutive weeks and detected that a statistically significant change in plaque volume of newborn plaques was achieved not earlier than 2 weeks after their first appearance (Fig. 3c), whereas a statistically significant change in plaque volume of pre-existing plaques was achieved not earlier than 4 weeks after the initial measurement (Fig. 4c).
A molecular imaging tracer, [C]-Pittsburgh compound B (PiB), which binds to Aβ plaques, has been used in small-animal and human PET (positron-emission tomography) imaging studies to monitor Aβ plaque load and its clearance in response to treatment [ 22].
Other researchers have used 3D US to monitor ulcerated plaques prospectively for more than a year, reporting that the vast majority of plaques (76.5%) remained unchanged, 23.5% of ulcerations regressed while only 5.8% of ulcerations progressed [61].
Now, two groups of researchers have demonstrated more-practical methods for monitoring the plaque development characteristic of Alzheimer's disease.
The plates were inverted, placed in a 37 °C and 5%% CO2 atmosphere (incubation period), and monitoring for plaque formation for 2 4 days.
